Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of S-648414 in Healthy Adults
NCT04147715Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of S-648414 in human immunodeficiency virus infection (HIV) (12 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Maximum Plasma Concentration at Day 28 and 4 more. Started Oct 2019; status: completed.
02
Drugs
S-648414
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04147715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147715.